David A. Reardon, MD, Professor, Medicine, Harvard Medical School; Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute
In an initial phase 1b trial, we demonstrated that neoantigen vaccination can generate neoepitope-specific CD4+ and CD8+ T cells in glioblastoma, an immunologically “cold” tumor with low mutational burden. Of note, concurrent corticosteroids abrogated vaccine induced immune responses. Finally, we confirmed that neoepitope-specific T cells can successfully traffic into intracranial GBM tumors. Updates on strategies to optimize our neoantigen approach and enhance its efficacy via combinatorial regimens will be reviewed.